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VASAbstract Background: Postdural puncture headache (PDPH) is a common complication after
lumbar puncture. Anesthesiologists are the most likely to be consulted for the treatment. PDPH
may be debilitating for a patient and can interfere with daily activities and quality of life.
Methods: Fifty patients of both sexes, aged 18–50 years and ASA I and II undergoing elective lower
abdominal and pelvic surgery under spinal anesthesia were included in this randomized double-blind
study. Patients were randomly divided into 2 groups 25 each: hydrocortisone group received intra-
venous hydrocortisone 100 mg every 8 h for 48 h and mannitol group received intravenous infusion
of mannitol 20% 100 ml over 30 min followed by 100 ml every 12hours. Mean (±SD) of headache
intensity at 0, 6, 12, 24 and 48 h after beginning of treatment was assessed using visual analogue scale.
Results: There was no signiﬁcant difference regarding headache intensity between two groups before
beginning of treatment. The VAS was signiﬁcantly reduced in hydrocortisone group than in mannitol
group at 6, 12, 24 h with P-value 0.030, 0.007, 0.004 respectively. At 48 h, both groups had nearly the
same VAS of headache intensity, with P-value 0.305.
Conclusion: Both intravenous hydrocortisone and mannitol intravenous infusion were efﬁcient in
reducing postdural puncture headache within 48 h. Hydrocortisone showed earlier and signiﬁcant
relief of headache.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
According to the International Classiﬁcation of Headache
Disorders (ICHD-II), postdural puncture headache (PDPH)
is iatrogenically conditioned orthostatic headache that follows
lumbar puncture, worsens within 15 min of sitting or standing
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pressure in the spinal ﬂuid space [1]. Ninety percent of PDPHs
occur within three days of the procedure and 66% start in the
ﬁrst 48 h [2]. Postdural puncture headache (PDPH) is usually
described as a severe, dull, non-throbbing pain, usually
fronto-occipital. It may be accompanied by nausea, vomiting,
visual disturbances and/or auditory disturbances. Headache
begins 1 or 2 days after spinal anesthesia and usually relieves
spontaneously within a week, but the patient suffers miserably
during this period [3].
The pathophysiology PDPH is due to CSF leakage from
the subarachnoid space through the dural puncture, resulting
in a decrease of CSF volume and pressure [4]. According to
Monro–Kellie–Burrows doctrine (the sum of the volumes of
CSF, the blood and the brain tissue in the skull remain con-
stant), loss of CSF may result in compensatory intracranial
vasodilatation. Relative CSF hypovolemia results in painful,
possibly adenosine-receptor-mediated, vasodilatation [5].
Headache continues until dural hole repairs and it is relieved
when CSF volume and pressure return to normal [6].
As a result of buoyancy in the CSF, the weight of the struc-
tures in the central nervous system is reduced to around 50 mg
[7]. An average human has approximately 150 ml of CSF
within the subarachnoid space. About 500 ml of CSF is pro-
duced per day, and at any time the volume of CSF ranges from
125 to 150 ml, half of which is intracranial. The lumbar CSF
pressure is 5–15 cm water but increases to 40 cm water in the
upright position. In patients with PDPH, the loss of CSF
(which may be as much as 12 ml/min) is greater than the rate
of replacement (approximately 0.35 ml/min) [8].
The resultant low intracranial pressure and relative deﬁcit
in CSF result in traction on pain-sensitive cranial structures
(e.g. blood vessels, meninges, and cranial nerves). The pain
associated with PDPH is most prominent in upright position.
This position exacerbates the traction on intracranial struc-
tures and increases transdural lumbar CSF pressure, promot-
ing further loss of CSF [8]. This pain is mediated by
substance P and the upregulation of neurokinin-1 receptors [9].
Treatment of PDPH is divided into 4 stages: conservative
management, aggressive medical management, conventional
invasive therapy, and aggressive invasive treatment. On aver-
age, move from conservative to aggressive medical therapy
occurred after several days, and from aggressive medical man-
agement to invasive treatment at about 4 days after onset of
PDPH. Choice of treatment was according to the severity of
symptoms [10].
Conservative management is appropriate because of the
benign prognosis of PDPH. Bed rest in horizontal position,
adequate hydration [11,12] and symptomatic treatment as
analgesics (acetaminophen, non-steroidal anti-inﬂammatory
drugs) are usually used. Antiemetics are used to obtain com-
fort till seal of the dura [13].
The Institute of Medicine determined that an adequate
intake (AI) of ﬂuid per day for men is roughly about 13 cups
(3 l) of total beverage a day. The AI for woman is about 9 cups
(2.2 l) of total beverage a day [14].
According to European Food Safety Authority (EFSA) on
dietary reference values for water, the water adequate intake
(AI) for adult men is 2500 ml/day and AI for women is
2000 ml/day to allow our body to perform optimally [15].
Aggressive medical management includes medications such
as methylxanthines (caffeine and aminophylline) [16–18] andTriptans [19]. Adrenocorticotropic hormone (ACTH), prega-
balin, gabapentin, and methergine with metoclopramide are
successfully used [20–24].
Conventional invasive treatment, epidural blood patch
(EBP) is used when conservative measures fail [25,26]. Other
invasive treatment options include the use of epidural saline
or dextran [27].
Sphenopalatine ganglion block is used for PDPH, without
signiﬁcant side effects or complications. The block is less inva-
sive and works faster than EBP [28].
Aggressive invasive treatment, is an alternative to EBP
when it fails to control PDPH. The diagnosis should be reeval-
uated. If conﬁrmed, percutaneous computed tomography(CT)-
guided injection of ﬁbrin glue aimed to seal the dural tear [29].
Surgical treatment is the last resort to stop a CSF leak and
cure PDPH [30].
The preventive effect of corticosteroids against PDPH can
be due to their anti-inﬂammatory effect on the inﬂammatory
process initiated at puncture site. Steroids suppress arachi-
donic acid production through lipocortin-induced phospholi-
pase inhibition, which inhibits production of prostaglandins
(PGE 2 and PGI 2), and leukotrienes (LTB 4). Also, corticos-
teroids block production of pro-inﬂammatory cytokines such
as interleukin-1, interleukin-2, and tumor necrosing factor-
alpha. The analgesic effect of steroids in PDPH, may relate
to their anti-inﬂammatory effects at dural puncture site.
During healing of dural puncture, inﬂammatory mediators
are secreted from immune cells, spread in CSF, stimulate pain
receptors, and cause headache. Steroids suppress production
of these allogenic mediators and relieve headache [31,32].
Mannitol is an osmotherapy exerting its cerebral effects via
two mechanisms, an immediate effect because of plasma
expansion and slightly delayed effect through its osmotic
action. The early plasma expansion decreases blood viscosity
and so improves regional microvascular cerebral blood ﬂow
and oxygenation. Also it increases intravascular volume and
therefore cardiac output. Both effects result in an increase in
regional cerebral blood ﬂow and compensatory cerebral vaso-
constriction in brain areas where autoregulation is intact,
reducing intracranial tension. The delayed effect is creating
an osmotic gradient between plasma and brain cells, drawing
water from the cerebral extracellular space into the vascula-
ture, thereby reducing brain weight [33]. The peak effect of
mannitol on intracranial pressure was achieved within
30–45 min and last around 6 h [34].
In this study, our primary measure was to compare between
hydrocortisone and mannitol in treatment of PDPH within
48 h. And our secondary measure of the study was to ﬁnd
out a non-invasive effective rapid treatment of PDPH.2. Methods
This study was designed to be a randomized double-blind par-
allel study in which patients, investigators and anesthesiolo-
gists were blinded to the given treatment. This study was
conducted between October 2014 and November 2015. A total
number of 167 patients scheduled for elective lower abdominal
and pelvic surgery e.g. repair of inguinal hernia, incisional
hernia, varicocele and hydrocele done under spinal anesthesia
were arranged to be enrolled in the study. A total of 57
patients developed PDPH and were assessed for eligibility
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the ethical committee in Heliopolis hospital (Cairo, Egypt), a
written consent was obtained from the ﬁfty patients aged
18–50 years of both sexes, ASA physical status I–II of
70–90 kg body weight and height 160–180 cm.
Patients with impaired kidney or liver functions, history
of cardiac or central nervous system disease (a history of
convulsions, cerebro-vascular accident, preeclampsia,
eclampsia or high intracranial pressure), history of drug or
alcohol abuse, history of chronic pain or daily intake of
analgesics, uncontrolled medical disease (diabetes mellitus
and hypertension), history of intake of non-steroidal
anti-inﬂammatory drugs or opioids within 24 h before surgery
or allergy to the used medications, coagulation defect, patient
refusal or duration of surgery more than 120 min were
excluded from the study.
Preoperatively, peripheral 18-gauge intravenous cannula
was inserted, and standard non-invasive blood pressure and
pulse rate were recorded. All patients received 20 ml/kg of
lactated Ringer’s solution as a pre-hydration measure over
30 min. Monitoring of the patients, hemoglobin oxygen
saturation (SpO2), mean arterial blood pressure (MAP), and
5-leads ECG were recorded by Dra¨ger Vista 120 prior to anes-
thesia and every 5 min intraoperatively. Granisetron (1 mg IV)
was given as a prophylactic antiemetic.
For all patients in the study, the spinal anesthesia was per-
formed at L3-4 or L4-5 with the patient in the sitting position,
midline approach with 25-gauge needle (UNIEVER K-3
LANCET, made in JAPAN) and hyperbaric bupivacaine
was administered after conﬁrmation of cerebrospinal ﬂuid
(MYLAN, anhydrous hydrochloride, hyperbaric solution ster-
ile, 20 mg/4 ml). Patients were placed immediately in supine
position. After ﬁxation of the upper sensory level, operation
was proceeded.
Signiﬁcant intraoperative hemodynamic changes as
hypotension or bradycardia (More than 20% of the recorded
baseline values) will be treated by intravenous administration
of ephedrine in 5 mg increments and atropine 0.4 mg respec-
tively. At the end of procedure, patients were transferred to
post anesthetic care unit (PACU) with monitoring of hemody-
namics and sensory level.
Patients with postoperative PDPH were randomly allocated
in two groups 25 each. Randomization was done using
computer-generated number table of random numbers in a
1:1 ratio and conducted using sequentially numbered, opaque
and sealed envelope (SNOSE). Hydrocortisone group, received
hydrocortisone 100 mg, dissolved in 2 ml normal saline, intra-
venously/8 h for 48 h (hydrocortisone as sodium succinate,
vial, equivalent to hydrocortisone 100 mg, Egyptian INT,
Pharmaceutical Industries CO. ARE,EIPI.CO.EGYPT) and
mannitol group, received mannitol 20% 100 ml intravenously
which was given over 30 min and followed by 100 ml on a
12hour basis for 48 h (Manufactured by Allmed Middle East,
Egypt). Urinary catheter was inserted for patients in mannitol
group under complete aseptic conditions by the anesthesia res-
ident before the start of mannitol infusion and removed after
its discontinuation, accompanied by the intravenous ﬂuid infu-
sion over 48 h of 500 ml of normal saline or Ringer’s solution
every 8 h and the input/output ﬂuid chart for evaluation of
ﬂuid balance. Treatment in both groups started once patient
complained of headache. The study drugs were prepared by
the anesthesia resident and follow -up of patients wasconducted by the same anesthesia resident not involved in
any other part of the study.
Postoperatively, severity of headache was assessed and
scored by 10-point visual analogue scale (VAS). The patients
were instructed on how to use VAS for the assessment of the
degree of headache (with 0 representing no headache and
10 cm representing the worst imaginable headache). According
to the degree of headache or pain given by the patient,
classiﬁcation of headache severity was done as follows: no
headache = 0, mild headache <3, moderate headache 4–6
and severe headache >7. VAS was recorded after 6 h, 12 h,
24 h, and 48 h after the start of the treatment in both groups
by the anesthesia resident not involved in any other part of
the study.
Assessment of postoperative hemodynamic variables such
as heart rate (HR) and mean arterial pressure (MAP) and
the monitoring of arterial SpO2 at 6, 12, 24, 36 and 48 h after
the start of the treatment in both groups were fulﬁlled.
2.1. Analysis of data
PASS 11 was used for sample size calculation, where a sample
size of 22 patients per group would achieve 80% power to
detect a difference of 50% in proportion of post-treatment
headache relief. The reference group proportion was 0.5. The
calculations assume that two-sided Z test was used. 25 patients
per group were intended to be included to replace any
dropouts.
The collected data were coded, tabulated, and statistically
analyzed using IBM SPSS statistics (Statistical Package for
Social Sciences) software version 22.0, IBM Corp., Chicago,
USA 2013.
Descriptive statistics were done: for quantitative data it was
minimum and maximum of the range as well as mean ± SD
(standard deviation) and for quantitative parametric data,
median, while it was done for qualitative data as number
and percentage.
Inferential analysis was done using 95% conﬁdence interval
as well as independent t-test in cases of two independent
groups with parametric data. In qualitative data, inferential
analysis for independent variables was done using Chi square
test for difference between proportions and Fisher’s Exact test
for variables with small expected numbers. The level of
signiﬁcance at P value <0.05 was signiﬁcant, otherwise non-
signiﬁcant.
3. Results
This study was conducted between October 2014 and Novem-
ber 2015. A total number of 167 patients scheduled for elective
lower abdominal and pelvic surgery e.g. repair of inguinal her-
nia, incisional hernia, varicocele and hydrocele done under
spinal anesthesia were arranged to be enrolled in the study
(Fig. 1). A total of 57 patients developed PDPH and were
assessed for eligibility (Fig. 1). Five patients were not included
in this study on account of patient’s refusal (3 patients) and
history of chronic analgesic consumption (2 patients). Out of
which 52 patients received study medications after randomiza-
tion and 50 patients completed the study (25 patients for each
group) and their data were included in the ﬁnal analysis
(Fig. 1). Two patients were considered as drop-outs after initial
Table 1 The demographic data.
Variable Measure Hydrocortisone (N= 25) Mannitol (N= 25) P
Age (years) Mean ± SD 36.4 ± 9.1 35.1 ± 7.7 ^0.553
Range 20.0–50.0 22.0–50.0
Sex (n, %) Male 15 (60.0%) 14 (56.7%) #0.793
Female 10 (40.0%) 11 (43.3%)
Weight (kg) Mean ± SD 76.4 ± 4.2 77.0 ± 4.2 ^0.549
Range 69.2–84.2 66.9–87.3
Height (cm) Mean ± SD 169.5 ± 5.8 170.5 ± 5.1 ^0.512
Range 160.0–180.0 162.0–180.0
Length of surgery (minutes) Mean ± SD 108.0 ± 8.6 105.7 ± 10.1 ^0.340
ASA (n, %) I 13 (53.3%) 14 (56.7%) #0.795
II 12 (46.7%) 11 (43.3%)
P> 0.05 was considered statistically non-signiﬁcant.
^ Independent t-test.
# Chi square test.
5 paents 
excluded
52 paents 
were 
randomized
26 patients in 
Hydroc. group 
57 paents developed PDPH
Paent refusal 
(3) 
Chronic 
analgesic 
consumpon (2)
1 Dropout
25 paents 
completed 
the study
167 patients underwent 
surgery under spinal 
anesthesia
26 patients in 
mannitol group 1 Dropout
25 paents 
completed 
the study
Figure 1 Flowchart of patients (study design).
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tistical analysis (two patients needed re-exploration on account
of the postoperative bleeding).
Results of the current study did not show any signiﬁcant
difference in the demographic data of the groups of patients
regarding age, sex (male to female ratio), body weight, height,
ASA physical status and the length of surgery in minutes as
shown in Table 1.
The VAS for headache intensity for both groups showed
non-signiﬁcant difference at the start of the study (0 h). But
headache intensity per VAS was reduced in both groups but
reduction was more signiﬁcant in hydrocortisone group at 6,
12, 24 h after the start of the treatment. At 48 h of the study,the VAS intensity for headache showed non-signiﬁcant differ-
ence between the two groups (Table 2).
The comparison of mean headache intensities between
both groups is plotted in Fig. 2. It showed reduction of head-
ache intensity for both groups during 48 h after treatment.
Patients of hydrocortisone group under hydrocortisone
treatment showed earlier at 6, 12, 24 h after the start of the
treatment and more reduction of headache rather than man-
nitol group under mannitol treatment throughout the time of
the study.
Table 3 and Fig. 3 compared the percentage of headache
relief in both study groups at each time of follow-up of the
patients.
Table 2 Visual analogue scale (VAS).
Time
points
Hydrocortisone
(N= 25)
Mannitol
(N= 25)
^P
Hour 0 9.0 (8–9) 9.0 (8–10) 0.714
Hour 6 3.0 (0–3) 3.0 (1.5–4) 0.030*
Hour 12 0.0 (0.0–1.0) 2.0 (0.0–3.0) 0.007*
Hour 24 0.0 (0.0–0.5) 0.0 (0.0–2.0) 0.004*
Hour 48 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.305
The VAS for headache intensity was expressed as median and
interquartile range (IQR).
^ Mann–Whitney test.
* Signiﬁcant.
Figure 2 Comparison of headache relief per VAS between the
two study groups.
Figure 3 Comparison between reduction of headache intensity
in the two groups.
Table 4 Input and output ﬂuids (ml) for mannitol group.
Variable Mean ± SD Range
Day-1 IV ﬂuid 1500.0 ± 0.0 1500.0–1500.0
Day-2 IV ﬂuid 1500.0 ± 0.0 1500.0–1500.0
Day-1 oral ﬂuid 1140.0 ± 161.0 900.0–1500.0
Day-2 oral ﬂuid 1078.3 ± 114.2 900.0–1300.0
Day-1 urine 1520.0 ± 144.8 1200.0–1800.0
Day-2 urine 1506.7 ± 191.1 1000.0–1800.0
Day-1 balance 1120.0 ± 220.3 700.0–1600.0
Day-2 balance 1071.7 ± 220.3 800.0–1500.0
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on mannitol treatment which was done for 48 h across the time
of the study. It evaluated the difference between ﬂuid input
both oral and intravenous and ﬂuid output through urine out-
put. After ﬁrst 24 h, the mean ± SD ﬂuid balance was 1120.0
± 220.3 ml, and after the second twenty-four hours, the mean
± SD ﬂuid balance was 1071.7 ± 220.3 ml. It denoted no
signs of dehydration with the dose of mannitol included in this
study.
No signiﬁcant changes were noted in the heart rate
(P= 0.289), the mean arterial blood pressure (P= 0.371)
and the SpO2 (P= 0.340) between the studied groups
throughout the study period.Table 3 Comparison between study groups regarding percentage o
Time points Measure Hydrocortisone (N= 25)
At 6 h n, % 9 (30.0%)
95% CI 13.6–46.4%
At 12 h n, % 21 (70.0%)
95% CI 53.6–86.4%
At 24 h n, % 28 (93.3%)
95% CI 84.4–100.0%
At 48 h n, % 29 (96.7%)
95% CI 90.3–100.0%
CI: Conﬁdence interval. n= number of patients relieved from headache.
# Chi square test.
^ Fisher exact test.
* Signiﬁcant.No signiﬁcant side effects of the studied drugs occurred
during the ﬁrst 48 h after the start of the treatment except
for two patients in hydrocortisone group complained of mild
ﬂushing and it was resolved spontaneously without treatment.
4. Discussion
This study compared IV hydrocortisone versus mannitol intra-
venous infusion in treatment of PDPH. It showed that 93.3%
of patients under treatment of hydrocortisone recovered from
headache treatment after 3 doses of hydrocortisone within
24 h, while 90% of patients on mannitol treatment showed
recovery from headache at 48 h. It denoted early treatment
of PDPH by hydrocortisone rather than mannitol. In addition,f headache relief throughout the study.
Mannitol (N= 25) ^P Diﬀerence (Eﬃcacy)
6 (20.0%) ^0.371 10.0%
5.7–34.3% 0.0–20.7%
13 (43.3%) ^0.037* 26.7%
25.6–61.0% 10.9–42.5%
19 (63.3%) ^0.005* 30.0%
46.1–80.6% 13.6–46.4%
27 (90.0%) #0.612 6.7%
79.3–100.0% 0.0–15.7%
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follow-up ﬂuid chart which is annoying to patients and
increased risk for urinary tract infections.
No signiﬁcant changes were noted in the heart rate, the
mean arterial blood pressure and the SpO2 between the studied
groups throughout the study period. No signiﬁcant side effects
of the studied drugs occurred during the ﬁrst 48 h after the
start of the treatment except for two patients in hydrocortisone
group complained of mild ﬂushing and it was resolved sponta-
neously without treatment.
Concomitant with our study, Turiel et al., proposed use of
Hydrocortisone in treatment of PDPH. In that study, patients
with severe spinal headache after cesarean section, received
hydrocortisone 100 mg IV every 8 h for 3 days. Headache dis-
appeared completely 12 h after last dose [35].
These results are in agreement with the ﬁndings of Neves
et al., who in their case series of three patients had reported
one woman with cesarean delivery who relived completely
from PDPH (after failure of conventional treatments of
PDPH) and two cases of dural puncture who did not develop
PDPH when IV hydrocortisone was administered prophylacti-
cally [31].
Our results were supported with the ﬁndings of Noyan Ash-
raf et al., who had demonstrated that IV hydrocortisone could
signiﬁcantly decrease the intensity of headache in women who
underwent cesarean section under spinal anesthesia in the 48 h
following surgical delivery [22].
Our results were consistent with the ﬁndings of Posso et al.,
who approved the efﬁcacy of single dose of intravenous hydro-
cortisone 1000 mg and dipyrone 1000 mg orally every 6 h and
venous hydration in treatment of PDPH in four female and
two male patients experiencing headache after spinal anesthe-
sia given for cesarean section, hemorrhoidectomy and knee
arthroscopy [36].
Tavakol et al. used dexamethasone 0.2 mg/kg (16 mg max-
imum) intravenously with 1000 mL normal saline within 2 h.
The ﬁndings showed that the mean pain score changed from
1.8 ± 6.5 to 1.2 ± 1.6 after treatment [37].
Hamzei et al., approved the efﬁcacy of dexamethasone
(8 mg) on PDPH and its incidence in cesarean section patients
in the ﬁrst 24 h and up to 1 week after surgery [38].
Doroudian et al., approved the use of intravenous (iv) dex-
amethasone (8 mg) prior to spinal anesthesia to limit the inci-
dence of PDPH and improve quality of life during the
postoperative period [39].
Jaun et al., showed effective prophylactic treatment of
PDPH by using one prophylactic dose of iv methylpred-
nisolone 500 mg within the ﬁrst two hours after dural puncture
in 10 patients out of 14 who underwent wide range of surgeries
under epidural anesthesia [40].
Gherghina et al., evaluated the efﬁcacy of intravenous
methylprednisolone in reducing headache after spinal anesthe-
sia in a study comparing the use of single dose of intravenous
methylprednisolone, 500 mg versus conventional therapy [41].
Hakim, showed that the administration of Cosyntropin
(ACTH) after accidental dural puncture was associated with
signiﬁcant reduction in the incidence of PDPH and the need
for therapeutic epidural blood patch [42].
In contrary to Hakim (2010) results, Rucklidge et al.,
administered a long acting ACTH analogue (Tetracosactin
zinc phosphate) or placebo to a series of 18 parturients withPDPH after deliberate or accidental dural puncture and failed
to demonstrate a difference in the severity of PDPH [43].
No studies were done using mannitol for treatment of
PDPH except for the study of Rizvi et al., which was in agree-
ment with our results, who used mannitol 20% for treatment
of PDPH in obstetric patients underwent cesarean section
under spinal anesthesia. Their results showed that the use of
mannitol 20% 100 ml infusion over ½ h followed by 100 ml
every 12 h settled PDPH after ﬁrst dose for 6–8 h and there
was no need for mannitol infusion after 48 h [44].
5. Conclusion
Meticulous follow-up for patients with PDPH is an important
responsibility of the anesthetic team. Hydrocortisone andMan-
nitol are effective noninvasive treatments for PDPH. But
hydrocortisone got earlier relief of PDPH and needs neither
urinary catheter insertion which was annoying to the patient,
with increased risk of urinary tract infections (UTI), nor
input/output ﬂuid chart which was an extra follow-up item.Strengths and limitations
Although hydrocortisone dose of the study was safe, adverse
effects of steroids should not be ignored (e.g. increased risk
of wound infection and delayed wound healing). Regarding
use of hydrocortisone in diabetic patients, follow-up for blood
sugar measurement should be done.Clinical trial registration
ClinicalTrials.gov Identiﬁer: NCT02760862.Conflict of interest
None.
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